Researchers at Northwestern University and Rice University have built an implantable device that produces three therapeutic drugs directly inside the body, solving a persistent engineering problem that has stalled similar efforts for years. The system keeps its drug-making cells alive for weeks by generating oxygen on the spot, a breakthrough described in a Northwestern announcement about the work published in the journal Device by Cell Press on March 27, 2026. If the approach scales beyond the lab, it could replace daily injections or pills for chronic conditions with a single implant that manufactures medicine on demand.
Why Earlier Implants Kept Failing
The idea of a “living pharmacy,” a device that uses engineered cells to produce medications inside a patient, has attracted significant federal investment and academic interest. But the core technical barrier has been simple biology: cells need oxygen to survive, and once sealed inside an implant and placed under the skin, they slowly suffocate. Without a reliable oxygen supply, cell viability declined steadily, and drug output dropped with it. Previous prototypes could keep cells functional for days, but not the weeks or months needed for a practical therapy.
That oxygen problem shaped the entire research agenda. Jonathan Rivnay, a Northwestern biomedical engineer who has been central to the living pharmacy effort, has described the architecture as a hybrid of engineered cells paired with supporting bioelectronics, where the electronic component must do more than just signal cells to release drugs. It also has to keep those cells breathing. Without that dual function, the implant is a short-lived novelty rather than a clinical tool.
Earlier attempts tried to solve the issue by relying on diffusion from nearby blood vessels or by packing in oxygen-rich materials, but those strategies were limited. Oxygen diffuses only so far through tissue and encapsulating membranes, and stored oxygen is quickly depleted. As a result, even sophisticated encapsulation systems saw their therapeutic cells enter stress states, reduce protein production, and eventually die. This bottleneck made the entire living pharmacy concept seem fragile: no matter how clever the genetic engineering, the biology would fail without a steady gas supply.
How HOBIT Splits Water to Make Oxygen
The new device, called HOBIT, attacks the oxygen shortage at its source. Rather than relying on the body’s own blood supply to deliver oxygen through the implant’s walls, the system splits nearby water molecules using an electrocatalytic process, producing oxygen directly where the cells live. The Northwestern and Rice team adapted this strategy from earlier work on an on-demand oxygen generation method designed to sustain transplanted therapeutic cells under low-oxygen stress.
HOBIT’s bioelectronic component sits adjacent to a chamber containing engineered cells. When the device is powered, the electrocatalyst drives water electrolysis at very low current densities, releasing oxygen into the cell compartment without generating damaging heat or bubbles at a scale that would disrupt tissues. Because the reaction uses water already present in the body’s fluids, the supply is effectively continuous as long as the electronics remain functional.
The practical result is that the drug-producing cells inside HOBIT stayed viable for weeks rather than days. That extended lifespan allowed the device to produce not just one but three distinct therapeutic molecules inside the body. Among the targets are compounds that regulate appetite and metabolism, according to the Northwestern researchers, who emphasize that the same platform could be reprogrammed to secrete other proteins or peptides. For patients with conditions requiring multiple daily medications, the difference between a device that lasts days and one that lasts weeks is the difference between a lab curiosity and something a doctor might actually prescribe.
The team’s earlier experiments, supported under a defense research program, showed that integrating oxygen generation with encapsulated cells could dramatically improve survival under hypoxic conditions. Those findings paved the way for HOBIT’s more complex architecture, which layers multi-drug production on top of long-term oxygen support.
A $43 Million Federal Bet on Internal Drug Factories
HOBIT did not emerge in isolation. It is part of a broader push by the federal government to fund implantable drug-production systems. The Advanced Research Projects Agency for Health, known as ARPA-H and housed within the U.S. Department of Health and Human Services, has framed real-time drug delivery and disease tracking as a strategic priority, highlighting living pharmacy concepts in its recent awards announcement.
One of the flagship efforts is the Mayo Clinic’s EASE project, which received a $43 million commitment from ARPA-H to develop a bioelectronic implant that can stimulate engineered cells to switch therapy production on and off. That project focuses on inflammatory bowel disease as an initial target, aiming to deliver anti-inflammatory biologics locally in the gut while minimizing systemic side effects.
The living pharmacy concept also has roots in earlier defense research. Northwestern has traced part of its collaboration to DARPA’s NTRAIN program, which explored whether implanted cells could produce therapeutic molecules for military applications such as rapid response to nerve agents or infectious threats. ARPA-H later picked up the idea with a civilian health focus, broadening the scope to chronic diseases that drive long-term health care costs.
Carnegie Mellon University has positioned itself in the same ecosystem with its BIO-INSYNC concept, which targets hormonal disorders and other systemic conditions as part of broader living pharmacy and sentinel efforts. Together, these projects indicate that federal agencies see internal drug factories not as speculative science fiction, but as a plausible next step in precision medicine.
What Three Drugs Actually Mean for Patients
Most coverage of the living pharmacy concept has focused on the engineering challenge of keeping cells alive. But the real clinical significance of HOBIT is the multi-drug capability. Producing a single molecule inside the body is useful. Producing three is a qualitative leap, because most chronic diseases require combination therapy. A patient with a metabolic disorder, for example, might need one drug to regulate appetite, another to manage insulin sensitivity, and a third to control inflammation. Packaging all three into a single implant could reduce the burden of complex regimens that involve multiple pills and injections each day.
The ability to engineer cells that respond to different electronic cues or chemical signals means a single device might eventually deliver tailored “cocktails” that shift over time. In principle, one could imagine an implant that starts by emphasizing weight loss, then gradually rebalances toward maintaining glucose control as a patient’s condition stabilizes. Instead of rewriting a prescription every few months, clinicians would adjust settings on a device already in place.
The concept of remote-controlled dosing adds another layer. The bioelectronic component of these devices is designed to let clinicians adjust drug output without surgery, potentially tuning therapy in response to disease flares or changing lab results. Depending on the final design, this control could be exercised through wired programming during clinic visits or through secure wireless links that log activity and enforce safety limits. For patients, that might translate into fewer hospitalizations during exacerbations of chronic disease, because therapy could be intensified early and then dialed back as markers improve.
At the same time, the shift from pills to implants raises new questions. Long-term safety will depend on making sure the oxygen-generating reaction does not damage tissues, that the encapsulated cells cannot escape or transform in unwanted ways, and that the electronics remain reliable over years. Regulatory agencies will also have to grapple with devices that blur the line between biologic drug, medical device, and software-controlled system.
Still, the underlying logic is straightforward: many of the most expensive and debilitating conditions in modern medicine stem from the body’s inability to produce the right molecules in the right amounts at the right times. By embedding programmable, oxygen-fed cell factories under the skin, researchers hope to turn those missing or misregulated molecules into something the body can receive continuously and automatically, rather than in sporadic doses from a pill bottle.
HOBIT’s demonstration that three drugs can be produced from a single, long-lived implant does not resolve all of those challenges. But it moves the field from proving that such systems can work at all to asking how they might best be integrated into everyday care. As federal agencies continue to back living pharmacy platforms and academic teams refine oxygen-generating electronics, the prospect of internal drug factories is shifting from speculative to tangible, one carefully engineered molecule of oxygen at a time.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
